319 related articles for article (PubMed ID: 15102698)
1. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity.
Yang SC; Hillinger S; Riedl K; Zhang L; Zhu L; Huang M; Atianzar K; Kuo BY; Gardner B; Batra RK; Strieter RM; Dubinett SM; Sharma S
Clin Cancer Res; 2004 Apr; 10(8):2891-901. PubMed ID: 15102698
[TBL] [Abstract][Full Text] [Related]
2. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma.
Yang SC; Batra RK; Hillinger S; Reckamp KL; Strieter RM; Dubinett SM; Sharma S
Cancer Res; 2006 Mar; 66(6):3205-13. PubMed ID: 16540672
[TBL] [Abstract][Full Text] [Related]
3. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo.
Sharma S; Stolina M; Luo J; Strieter RM; Burdick M; Zhu LX; Batra RK; Dubinett SM
J Immunol; 2000 May; 164(9):4558-63. PubMed ID: 10779757
[TBL] [Abstract][Full Text] [Related]
4. EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model.
Hillinger S; Yang SC; Zhu L; Huang M; Duckett R; Atianzar K; Batra RK; Strieter RM; Dubinett SM; Sharma S
J Immunol; 2003 Dec; 171(12):6457-65. PubMed ID: 14662845
[TBL] [Abstract][Full Text] [Related]
5. Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma.
Sharma S; Stolina M; Zhu L; Lin Y; Batra R; Huang M; Strieter R; Dubinett SM
Cancer Res; 2001 Sep; 61(17):6406-12. PubMed ID: 11522634
[TBL] [Abstract][Full Text] [Related]
6. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
7. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer.
Baratelli F; Takedatsu H; Hazra S; Peebles K; Luo J; Kurimoto PS; Zeng G; Batra RK; Sharma S; Dubinett SM; Lee JM
J Transl Med; 2008 Jul; 6():38. PubMed ID: 18644162
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
Matsuyoshi H; Hirata S; Yoshitake Y; Motomura Y; Fukuma D; Kurisaki A; Nakatsura T; Nishimura Y; Senju S
Cancer Sci; 2005 Dec; 96(12):889-96. PubMed ID: 16367909
[TBL] [Abstract][Full Text] [Related]
9. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
[TBL] [Abstract][Full Text] [Related]
10. SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10.
Sharma S; Yang SC; Hillinger S; Zhu LX; Huang M; Batra RK; Lin JF; Burdick MD; Strieter RM; Dubinett SM
Mol Cancer; 2003 Apr; 2():22. PubMed ID: 12740040
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication.
Miller PW; Sharma S; Stolina M; Butterfield LH; Luo J; Lin Y; Dohadwala M; Batra RK; Wu L; Economou JS; Dubinett SM
Hum Gene Ther; 2000 Jan; 11(1):53-65. PubMed ID: 10646639
[TBL] [Abstract][Full Text] [Related]
12. Phase I Trial of Intratumoral Injection of
Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
[No Abstract] [Full Text] [Related]
13. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination.
Matsuyoshi H; Senju S; Hirata S; Yoshitake Y; Uemura Y; Nishimura Y
J Immunol; 2004 Jan; 172(2):776-86. PubMed ID: 14707047
[TBL] [Abstract][Full Text] [Related]
14. Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector.
Terando A; Roessler B; Mulé JJ
Cancer Gene Ther; 2004 Mar; 11(3):165-73. PubMed ID: 14726959
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT.
Hisada M; Yoshimoto T; Kamiya S; Magami Y; Miyaji H; Yoneto T; Tamada K; Aoki T; Koyanagi Y; Mizuguchi J
Cancer Gene Ther; 2004 Apr; 11(4):280-8. PubMed ID: 15002032
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells.
Riedl K; Baratelli F; Batra RK; Yang SC; Luo J; Escuadro B; Figlin R; Strieter R; Sharma S; Dubinett S
Mol Cancer; 2003 Nov; 2():35. PubMed ID: 14613584
[TBL] [Abstract][Full Text] [Related]
17. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity.
Tolba KA; Bowers WJ; Muller J; Housekneckt V; Giuliano RE; Federoff HJ; Rosenblatt JD
Cancer Res; 2002 Nov; 62(22):6545-51. PubMed ID: 12438249
[TBL] [Abstract][Full Text] [Related]
18. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy.
Kirk CJ; Hartigan-O'Connor D; Nickoloff BJ; Chamberlain JS; Giedlin M; Aukerman L; Mule JJ
Cancer Res; 2001 Mar; 61(5):2062-70. PubMed ID: 11280767
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
[TBL] [Abstract][Full Text] [Related]
20. Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells.
Guo J; Zhang M; Wang B; Yuan Z; Guo Z; Chen T; Yu Y; Qin Z; Cao X
Int J Cancer; 2003 Jan; 103(2):212-20. PubMed ID: 12455035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
